A small number of pharmacy benefit managers dominated the Medicare Part D, Medicaid and commercial markets in 2023, and the three biggest PBMs may each be targeting different payer markets, according to new USC Schaeffer Center research published Sept. 10 in JAMA.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.